Provided by Tiger Fintech (Singapore) Pte. Ltd.

Akoya Biosciences, Inc.

1.22
+0.01000.83%
Volume:212.62K
Turnover:262.41K
Market Cap:60.78M
PE:-1.09
High:1.27
Open:1.19
Low:1.19
Close:1.21
Loading ...

BRIEF-Akoya Biosciences - On April 2, Entered Securities Purchase Agreement With Quanterix Corporation

Reuters
·
04 Apr

Akoya Biosciences - on April 2, Entered Securities Purchase Agreement With Quanterix Corporation

THOMSON REUTERS
·
04 Apr

Akoya Biosciences Inc -Pursuant to Securities Purchase Agreement, Co to Issue Convertible Notes up to $30 Million - SEC Filing

THOMSON REUTERS
·
04 Apr

Akoya Biosciences, Team SAMBAI announce selection of PhenoCycler-Fusion

TIPRANKS
·
02 Apr

Akoya Biosciences and Team SAMBAI Announce Selection of the PhenoCycler®-Fusion as the Foundational Spatial Proteomics Technology for Large-Scale Study to Address Cancer Inequities

GlobeNewswire
·
02 Apr

Akoya Biosciences Shares Fall After Downgrade From Stephens

MT Newswires Live
·
26 Mar

Akoya Biosciences Cut to Equal-Weight From Overweight by Stephens & Co.

Dow Jones
·
25 Mar

Stephens Downgrades Akoya Biosciences to Equalweight From Overweight, Price Target is $1.80

MT Newswires Live
·
25 Mar

Cautious Outlook on Akoya Biosciences Amid Acquisition Uncertainties and Mixed Financial Performance

TIPRANKS
·
25 Mar

BRIEF-Tikvah Management Announces Intention to Vote AGAINST Quanterix’s Proposed Merger with Akoya Biosciences

Reuters
·
24 Mar

Tikvah Management- Announces Intention to Vote Against Quanterix's Proposed Merger With Akoya Biosciences

THOMSON REUTERS
·
24 Mar

Hold Rating on Akoya Biosciences Amid Acquisition Uncertainties and Financial Challenges

TIPRANKS
·
24 Mar

North American Morning Briefing: Stock Futures Rise on Tariff Optimism

Dow Jones
·
24 Mar

Akoya Biosciences Price Target Maintained With a $3.50/Share by Stephens & Co.

Dow Jones
·
18 Mar

Q4 2024 Quanterix Corp Earnings Call

Thomson Reuters StreetEvents
·
18 Mar

Akoya Biosciences (AKYA) Reports Q4 Loss, Lags Revenue Estimates

Zacks
·
18 Mar

Akoya Biosciences Q4 2024 GAAP EPS $(0.17) Misses $(0.16) Estimate, Sales $21.344M Beat $21.338M Estimate

Benzinga
·
18 Mar

Akoya Biosciences Inc Q4 Shr View $-0.16, REV View $21.3 Mln -- Lseg Ibes Data

THOMSON REUTERS
·
18 Mar

Akoya Biosciences Inc Qtrly Revenue Was $21.3 Million

THOMSON REUTERS
·
18 Mar

Press Release: Akoya Reports Fourth Quarter of 2024 and Full Year Financial Results

Dow Jones
·
18 Mar